A 14% jump in topline for German Remedies when the domestic formulations are growing by 7–8% is very creditable. More creditable is the improvement in operating margins and a near 40% growth in the bottomline despite a 60% jump in the depreciation provision and a 70% reduction in the other income.
(Rs m) | 3QFY2000 | 3QFY1999 | Change |
Net Sales | 489.5 | 429.8 | 13.9% |
Other Income | 1.7 | 5.7 | -70.5% |
Total Expenditure | 408.8 | 371.2 | 10.1% |
Interest | 3.1 | 4.2 | -24.8% |
Depreciation | 17.0 | 10.1 | 68.5% |
Profit before Tax | 62.3 | 50.1 | 24.4% |
Tax | 5.9 | 9.4 | -37.8% |
Profit after Tax/(Loss) | 56.4 | 40.7 | 38.5% |
Net profit margin (%) | 11.5% | 9.5% |
Sorry! There are no related views on news for this company/sector.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.
What should you do if the market falls? In this video, I'll tell you what I will do.
Ajit Dayal on how India's vaccine strategy will impact the markets.
More
Equitymaster requests your view! Post a comment on "Impressive results from German Remedies". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!